Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resistance risk.
Atea Pharmaceuticals’ Hepatitis C Virus Candidate Shows Efficacy
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell
• Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
Atea Pharmaceuticals’s Earnings Outlook
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Wednesday, 2023-11-08. Here’s what investors…
Benzinga’s Top Ratings Upgrades, Downgrades For August 10, 2023
Upgrades For Roblox Corp (NYSE:RBLX), Wedbush upgraded the previous rating of Neutral to Outperform. Roblox earned $0.46 in…
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Atea Pharmaceuticals Confirms Receipt Of Unsolicited Proposal From Tang Capital Partners’ Affiliate, Concentra Biosciences To Acquire All Outstanding Common Shares Of Atea For $5.75/Share In Cash, Plus 80% Payable From Any License Or Disposition
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea") confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of
Biotech Bargain Hunt: Concentra Biosciences Eyes Atea’s Promising COVID-19 Response
Earlier today, Concentra Biosciences, an affiliate of Tang Capital, sent an acquisition proposal to Atea Pharmaceuticals Inc (NASDAQ: AVIR) at $5.75 per share, representing a 55% premium to Friday’s closing price, and a CVR re
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Microbot Medical (NASDAQ:MBOT) stock rose 152.0% to $3.1 during Monday’s regular session. As of 13:30 EST, Microbot…